PIERIS PHARMACEUTICALS, INC. (37)

Browse by Contract Category

Contracts

Employment Contract by and between Pieris Pharmaceuticals GmbH and Tim Demuth, M.D., Ph.D., dated as of August 1, 2021 (Filed With SEC on May 11, 2022)
Research Collaboration and License Agreement, dated May 19, 2021, by and among Pieris Pharmaceuticals, Inc., Pieris Pharmaceuticals GmbH and Genentech, Inc (Filed With SEC on August 5, 2021)
Exclusive Product License Agreement, dated April 24, 2021, by and among Pieris Pharmaceuticals, Inc., Pieris Pharmaceuticals GmbH and BP Asset XII, Inc (Filed With SEC on August 5, 2021)
Exchange Agreement by and among Pieris Pharmaceuticals, Inc. and Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS, L.P., and... (Filed With SEC on May 21, 2021)
Combination Study Agreement, dated March 24, 2021, by and among Pieris Pharmaceuticals, Inc. and Seagen Inc (Filed With SEC on May 17, 2021)
Amendment No. 2 to Lease Agreement by and between Pieris GmbH and Hallbergmoos Grundvermgen GmbH, dated February 13, 2020 (English translation) (Filed With SEC on March 13, 2020)
Non-Employee Director Compensation Policy, as amended (Filed With SEC on March 2, 2022)
Employment Agreement by and between Pieris Pharmaceuticals, Inc. and Tom Bures, dated as of October 7, 2021 (Filed With SEC on November 2, 2021)
Employment Agreement by and between Pieris Pharmaceuticals, Inc. and Ahmed Mousa, dated as of October 7, 2021 (Filed With SEC on November 2, 2021)
Pieris Pharmaceuticals, Inc. 2020 Employee, Director and Consultant Equity Incentive Plan, as Amended (Filed With SEC on June 29, 2021)
Subscription Agreement, dated March 29, 2021, by and between Pieris Pharmaceuticals, Inc. and AstraZeneca AB (Filed With SEC on May 17, 2021)
Amendment No. 1, dated March 29, 2021, to the Non-Exclusive Anticalin Platform License Agreement, dated May 2, 2017, by and between Pieris Pharmaceuticals, Inc. and AstraZeneca AB (Filed With SEC on May 17, 2021)
Amendment No. 2, dated March 29, 2021, to the License and Collaboration Agreement, dated May 2, 2017, by and between Pieris Pharmaceuticals, Inc. and AstraZeneca AB (Filed With SEC on May 17, 2021)
Subscription Agreement, dated March 24, 2021, by and between Pieris Pharmaceuticals, Inc. and Seagen Inc (Filed With SEC on May 17, 2021)
Amended and Restated License and Collaboration Agreement, dated March 24, 2021, by and between Pieris Pharmaceuticals, Inc. and Seagen Inc (Filed With SEC on May 17, 2021)
Clinical Trial Collaboration and Supply Agreement, dated August 10, 2020, by and between Pieris Pharmaceuticals, Inc. and Eli Lilly and Company (Filed With SEC on November 4, 2020)
Amendment No. 1 to the February 8, 2018 License and Collaboration Agreement by and among Pieris Pharmaceuticals, Inc. and Pieris Pharmaceuticals GmbH and Seattle Genetics, Inc (Filed With SEC on August 10, 2020)
Amendment No. 1 to the February 8, 2018 Platform Agreement by and among Pieris Pharmaceuticals, Inc. and Pieris Pharmaceuticals GmbH and Seattle Genetics, Inc (Filed With SEC on August 10, 2020)
Pieris Pharmaceuticals, Inc. 2020 Employee, Director and Consultant Equity Incentive Plan (Filed With SEC on June 29, 2020)
Exchange Agreement by and among Pieris Pharmaceuticals, Inc. and Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., and Biotechnology Value Trading Fund OS, L.P.,... (Filed With SEC on April 6, 2020)
Amendment No. 1 to Lease Agreement by and between Pieris GmbH and Hallbergmoos Grundvermgen GmbH, dated May 21, 2019 (English translation) (Filed With SEC on March 13, 2020)
Non-Employee Director Compensation Policy, as amended (Filed With SEC on March 13, 2020)
Letter Agreement by and between the Registrant and Louis A. Matis, M.D., dated as of January 8, 2020 (Filed With SEC on March 13, 2020)
Letter Amendment to the License and Collaboration Agreement by and between Les Laboratoires Servier, Institut de Recherches Internationales Servier, Pieris Pharmaceuticals, Inc.... (Filed With SEC on March 13, 2020)
Description of Registered Securities (Filed With SEC on March 13, 2020)
Non-Qualified Stock Option Agreement by and between the Registrant and Hitto Kaufmann, Ph.D., dated as of August 30, 2019 (Filed With SEC on November 12, 2019)
Managing Director Services Agreement by and between Pieris Pharmaceuticals GmbH and Hitto Kaufmann, PhD., dated February 20, 2019 (Filed With SEC on November 12, 2019)
Registration Rights Agreement, dated November 2, 2019, by and among the Company and the Investors named therein (Filed With SEC on November 4, 2019)
Form of Warrant to purchase Common Stock (Filed With SEC on November 4, 2019)
Securities Purchase Agreement, dated November 2, 2019, by and among the Company and the Investors named therein (Filed With SEC on November 4, 2019)
Open Market Sale Agreement, dated as of August 9, 2019, by and between Pieris Pharmaceuticals, Inc. and Jefferies LLC (Filed With SEC on August 9, 2019)
Pieris Pharmaceuticals, Inc. Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on August 9, 2019)
Subtenant Recognition and Attornment Agreement, by and among Pieris Pharmaceuticals, Inc., 225 State Street, LLC, and Berenberg Capital Markets LLC, dated as of May 31, 2019 (Filed With SEC on August 9, 2019)
Pieris Pharmaceuticals, Inc. 2019 Employee, Director and Consultant Equity Incentive Plan (Filed With SEC on July 31, 2019)
Non-Employee Director Compensation Policy, as amended (Filed With SEC on March 18, 2019)
Lease Agreement by and between Pieris GmbH and Hallbergmoos Grundvermgen GmbH, dated October 24, 2018 (Filed With SEC on March 18, 2019)
Exchange Agreement by and among Pieris Pharmaceuticals, Inc. and Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., and Biotechnology Value Trading Fund OS, L.P.,... (Filed With SEC on February 4, 2019)